Alaunos director granted 8,789 shares of stock

Vieser Jaime reported acquisition or exercise transactions in this Form 4 filing.

Accepted by SEC EDGAR 07/27/2026 - 04:15 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Vieser Jaime reported acquisition or exercise transactions in this Form 4 filing.

Alaunos Therapeutics, Inc. director Jaime Vieser reported an equity compensation grant of 8,789 shares of common stock on 2026-07-23, valued at $1.92 per share and issued in lieu of board fees. Following this award, he holds 47,642 shares directly. The report also lists indirect holdings of 2,100 shares held by his children and 13,503 shares held by Brushwood LLC, where he serves as Manager.

Insider Trade Summary

Grant/Award: 8,789 shares

Grant/Award 1 txn

Insider Vieser Jaime

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock F1	8,789	$1.92	$17K
Holding	Common Stock	--	--	--
Holding	Common Stock F2	--	--	--

Holdings After Transaction: Common Stock — 47,642 shares (Direct); Common Stock — 2,100 shares (Indirect, by Reporter's children); Common Stock — 13,503 shares (Indirect, By Brushwood LLC)

Footnotes (2)

1. F1. Represents shares of common stock issued in lieu of board fees.
2. F2. The shares are directly held by Brushwood LLC. The Reporting Person is the Manager of Brushwood LLC.

Key Figures

Shares granted: 8,789 shares Grant price: $1.92 per share Direct holdings after grant: 47,642 shares +2 more

5 metrics

Shares granted 8,789 shares Common stock grant issued in lieu of board fees on 2026-07-23

Grant price $1.92 per share Valuation used for the 8,789-share common stock grant

Direct holdings after grant 47,642 shares Total common stock directly held by Jaime Vieser following the award

Indirect holdings (children) 2,100 shares Common stock held indirectly by the reporter's children

Indirect holdings (Brushwood LLC) 13,503 shares Common stock held indirectly through Brushwood LLC, managed by the reporter

Key Terms

issued in lieu of board fees, indirect ownership, Manager of Brushwood LLC

3 terms

issued in lieu of board fees financial

"Represents shares of common stock issued in lieu of board fees."

indirect ownership financial

"The shares are indirectly held, including by the reporter's children and Brushwood LLC."

Manager of Brushwood LLC financial

"The shares are directly held by Brushwood LLC. The Reporting Person is the Manager of Brushwood LLC."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Alaunos Therapeutics (TCRT) director Jaime Vieser report?

Jaime Vieser reported a grant of 8,789 shares of Alaunos Therapeutics common stock on 2026-07-23. The shares were issued in lieu of board fees and increased his directly held position to 47,642 shares.

How many Alaunos Therapeutics (TCRT) shares were granted to Jaime Vieser and at what price?

He received 8,789 shares of Alaunos Therapeutics common stock at $1.92 per share. The award is described as shares issued in lieu of board fees, reflecting equity-based compensation for his role as a director.

What are Jaime Vieser’s total direct and indirect Alaunos Therapeutics (TCRT) holdings after the grant?

After the grant, he holds 47,642 shares directly. Indirectly, the report lists 2,100 shares held by his children and 13,503 shares held by Brushwood LLC, where he is the Manager, in addition to his direct holdings.

Was the Alaunos Therapeutics (TCRT) share grant to Jaime Vieser related to board compensation?

Yes. The filing states the 8,789-share grant represents common stock issued in lieu of board fees. This indicates the transaction reflects equity compensation rather than an open-market purchase by the director.

Does the Alaunos Therapeutics (TCRT) Form 4 indicate use of a Rule 10b5-1 trading plan?

No. The report’s Rule 10b5-1 checkbox is not marked as affirming that the transactions were made under a Rule 10b5-1 trading plan. The grant is characterized instead as stock issued in lieu of board fees.

How are the Brushwood LLC holdings in Alaunos Therapeutics (TCRT) attributed in the report?

The report shows 13,503 shares held indirectly through Brushwood LLC. A footnote explains the shares are directly held by Brushwood LLC and that Jaime Vieser is the Manager of Brushwood LLC, linking him to that position.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Vieser Jaime

(Last) (First) (Middle)

501 E LAS OLAS BLVD

SUITE 300

(Street)

FORT LAUDERDALE FLORIDA 33301

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Alaunos Therapeutics, Inc. [ TCRT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/23/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/23/2026		A		8,789(1)	A	$1.92	47,642	D
Common Stock								2,100	I	by Reporter's children
Common Stock								13,503(2)	I	By Brushwood LLC(2)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares of common stock issued in lieu of board fees.

2. The shares are directly held by Brushwood LLC. The Reporting Person is the Manager of Brushwood LLC.

	Vieser Jaime	07/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)